Navigation Links
Pharmion Corporation Announces 2007 Operating Results
Date:2/19/2008

announced in August, the increasing uptake of Vidaza for European named patient and compassionate use that fueled Vidaza sales growth during the year, as well as significant progress in clinical research across our product portfolio, including the initiation of clinical studies for Amrubicin, MGCD0103 and oral Azacitidine."

2007 Financial Highlights

Pharmion reported a net loss of $(63.9) million, or $(1.81) per share for the year ended December 31, 2007, and a net loss of $(27.5) million, or $(0.74) for the fourth quarter of 2007. These losses include $8.6 million of expenses incurred in connection with the Company's pending acquisition by Celgene Corporation announced in November 2007 as well as charges for stock compensation expense of $5.7 million for 2007 and $1.5 million for the fourth quarter of 2007. In addition, the losses for year ended December 31, 2007 include a charge of $8 million for a milestone payment triggered by the acceptance of Pharmion's marketing authorization application (MAA) for Satraplatin for the treatment of second-line hormone-refractory prostate cancer by the European Medicines Agency (EMEA).

Research and development expenses totaled $102.4 million and $30.4 million for the full year and fourth quarter of 2007, respectively. These amounts compare to research and development expenses for the full year and fourth quarter of 2006 of $70.1 million and $20.0 million, respectively. The increase in R&D spending for 2007 was expected and was due primarily to development expenses incurred for the initiation of Phase 2 and 3 studies in small cell lung cancer (SCLC) for Amrubicin, the initiation of Phase 1 and 2 studies in solid tumors and chronic lymphocytic leukemia (CLL) for MGCD0103, the opening of centers and enrolling of patients in the dose escalation study for oral Azacitidine and the initiation of our research collaboration program with MethylGene Inc. targeting sirtuin inhibitors.

Selling, general and admini
'/>"/>

SOURCE Pharmion Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Pharmion Corporation to Announce Third Quarter 2007 Financial Results
2. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkins Lymphoma
3. Pharmion Corporation to Present at Bear Stearns 2007 Healthcare Conference
4. Pharmions Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes
5. Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
6. Verenium Corporation to Present at Piper Jaffray Clean Technology & Renewables Conference
7. VLST Corporation Announces Board and Executive Management Appointments
8. AGA Medical Corporation Receives European CE Mark Approval for the AMPLATZER(R) Duct Occluder II
9. AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe
10. LifeCell Corporation Revises Full Year 2007 Preliminary Results and Schedules Fourth Quarter 2007 Financial Results Conference Call; February 27, 2008 at 10:00 a.m. Eastern
11. Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014 The science of light and ... with more than 200 primary students in a traveling ... University of Otago Physics Department and funded by an ... members of the university’s OSA/SPIE Student Chapter visited six ... giving children from small, rural schools hands-on lessons in ...
(Date:11/21/2014)... 20, 2014 The November 2014 issue ... an open access journal featuring the following articles:, ... to preserve photoresponsiveness in the retina , ... situ hybridization using chromogenic substrates in zebrafish , ... and protein electrophoresis , Nuclear LC3-positive puncta ...
(Date:11/21/2014)... , Nov. 20, 2014 Polaris Group ... dosed in its Phase 1 trial of ADI-PEG ... the treatment of malignant pleural mesothelioma (MPM) and ... conducting clinical trials on ADI-PEG 20, both as ... the treatment of several other indications, including breast ...
(Date:11/18/2014)... Sarasota, FL (PRWEB) November 17, 2014 ... novel point-of-care diagnostic tests – today announces its ... Control and Prevention’s (CDC) Get Smart About Antibiotics ... Antibiotics Week is a national campaign designed to ... local health departments, and non-profit and for-profit partners ...
Breaking Biology Technology:Optics and photonics outreach programs share science, spark fascination with light 2Optics and photonics outreach programs share science, spark fascination with light 3BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 3
... CAMBRIDGE, England, June 25 ... service discovery services company at the,forefront of drug discovery ... Ahmedabad, India offering physio-chemical and CYP450 assays. , ... Biology Affiliate Partnership with,Hypoxium Ltd. UK. Hypoxium has specialist ...
... announced the winners of the NWO/Spinoza Prize for 2009. Two ... authors, Marten Scheffer and Albert van den Berg. The prize, ... Dutch award in science and is given for outstanding, pioneering ... EUR 1.5 million, but this year, each of the three ...
... June 24 KBI Biopharma, Inc. (KBI) announced today ... line generation with Crucell,s PER.C6(R) human cell line platform, ... on May 6, 2009. Under that agreement, KBI joins ... generation partner for licensees of the PER.C6(R) cell lines. ...
Cached Biology Technology:O2h and Hypoxium Announce an Agreement to Offer Hypoxium's Specialised In Vitro, Cell-Based Oncology Assays via O2h's Biology Affiliate Program 2KBI Biopharma Starts Cell Line Generation Process under Vendor Network Agreement for PER.C6(R) 2
(Date:11/4/2014)... Nov. 5, 2014 – University of Utah engineers developed ... help jet fuel produce electricity without needing to ignite ... to power portable electronics, off-grid power and sensors. , ... in the American Chemical Society journal ACS Catalysis ... a chemical reaction between a fuel and an oxygen-rich ...
(Date:11/4/2014)... 4, 2014   ...   Fuel3D , a developer of 3D ... round totaling $6.4 million (£4 million). This funding builds on ... this year and paves the way for the commercial launch ... The funding round was led by Chimera Partners and will ...
(Date:11/3/2014)... 3, 2014  NeuroSigma ® , Inc. (NeuroSigma), ... company focused on commercialization of its non-invasive ... treatment of neurological and neuropsychiatric disorders, announced today ... issued a Notice of Allowance for Mexican Patent ... by NeuroSigma and the Regents of the University ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... December 10, 2013, Shenzhen, China - Chinese researchers ... Medicine, BGI and other institutes identified the recurrent ... Yang 1) are related with insulinoma oncogenesis, implicating ... of functional pancreatic neuroendocrine tumors (PNETs). The latest ...
... has one of the fastest growing human populations in the ... density isn,t yet that high, the number of conflicts between ... on land areas grows. Angela Mwakatobe, who recently defended ... (NTNU) in Trondheim, has studied villages at various distances from ...
... a study led by McGill researcher Sarah Kimmins suggests that ... role in the health of their offspring. It also raises ... of food insecurity. The research focused on vitamin B9, ... green leafy vegetables, cereals, fruit and meats. It is well ...
Cached Biology News:Scientists identified T372R mutation as potential target for diagnosis and treatment of insulinoma 2Serengeti's animals under pressure 2Serengeti's animals under pressure 3You are what your father eats 2
Goat Anti-Horse IgG(T) Antibody, Unconjugated...
Identify and characterize Phosphoinositide (PI(3,4,5)P3) binding...
Mouse polyclonal antibody to MCFD2 - multiple coagulation factor deficiency 2...
Rabbit polyclonal to ErbB 2 (phospho Y1248) ( Abpromise for all tested applications). entrezGeneID: 2064 SwissProtID: P04626...
Biology Products: